A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma

A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma

Background: Lung adenocarcinoma (LUAD) is one of the most frequent types of lung cancer, with a high mortality and recurrence rate. This study aimed to design a RiskScore to predict the prognosis and immunotherapy response of LUAD patients due to a lack of metabolic and immune-related prognostic mod...

Full description

Bibliographic Details
Main Authors: Xiaolong Tang, Chumei Qi, Honghong Zhou, Yongshuo Liu
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Heliyon
Subjects:
Lung adenocarcinoma
Prognostic
Tumor immunity
DKK1
CCL20
NPAS2
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844022014529

Internet

http://www.sciencedirect.com/science/article/pii/S2405844022014529

Similar Items